BASKING RIDGE, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level…
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics…
Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumorsNEW YORK, April…
Failure to tender shares could result in the termination of the proposed merger between Chembio and BiosynexMEDFORD, N.Y., April 19,…
- Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive impact on an array of…
LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical…
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it…
Next generation robotics company to expand adoption of their Galaxy System and accelerate R&D for non-invasive platforms for patient diagnosis…
VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung fibrosis and hydroxyproline levels compared…